"Metastatic renal cell carcinoma" trang 1 - tải miễn phí từ tailieunhanh
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
4    74    1
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan
7    68    1
Optimal sequencing of the first-and second-line target therapies in metastatic renal cell carcinoma: Based on nationally representative data analysis from the Korean National Health Insurance System

Optimal sequencing of the first-and second-line target therapies in metastatic renal cell carcinoma: Based on nationally representative data analysis from the Korean National Health Insurance System
13    6    1
Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy
10    6    1
Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions

Single-cell analysis of immune and stroma cell remodeling in clear cell renal cell carcinoma primary tumors and bone metastatic lesions
21    9    1
DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma

DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
16    77    3
The PRO-RCC study: A long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs

The PRO-RCC study: A long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for ‘Trial within Cohorts’ study designs
8    1    1
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK
9    93    1
Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
9    56    1
Changes in therapy and survival of metastatic renal cell carcinoma in Estonia

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
7    60    0
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study
11    50    1
Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
12    62    1
Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis
9    36    1
Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
10    38    1
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors
10    57    1
Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry
11    45    1
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
9    38    1
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine
7    46    1
Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma

Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma
17    20    1
Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: A prospective cohort study

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: A prospective cohort study
9    45    1